FAQ
Log In
Saturday 3rd December 2016
News
 › 
 › 

Unlicensed herbal remedy warning

22nd June 2011

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned consumers not to take a herbal product called Beline to treat arthritis.

arthritis

The product, which is illegal in the UK, is made by FocusHR Limited and can be bought over the internet or by mail order.

An ingredient in the product called chlorphenamine is not listed as one of Beline's ingredients and is an antihistamine.

It can lead to side-effects in people who are allergic to antihistamines and cause problems for people with conditions such as bronchitis, asthma, epilepsy, heart disease, high blood pressure and poor liver function.

Beline's side-effects can include drowsiness, fatigue, dry mouth, blurry vision, nausea, headaches and attention problems.

The MHRA released a statement which stated that people should not buy and take Beline capsules, "due to concerns about the presence of a medicinal ingredient with the potential to cause side-effects".

The agency added "Anyone currently using this product should stop taking it and consult their healthcare professional immediately with the details contained in this notification."

A spokesman for Arthritis Research UK said people who suffered from arthritis needed to "exercise caution" when taking alternative medicines.

 

Share this page

Comments

There are no comments for this article, be the first to comment!


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: Unlicensed herbal remedy warning
Author: Jess Laurence
Article Id: 18879
Date Added: 22nd Jun 2011

Sources

Arthritis Research UK

Recent Related Articles

Warning over public defibrillators

Actions

Add to scrapbook
Show Comments
Add comment
Find all related articles

Tags

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016